Pulse Biosciences (PLSE) investor relations material

Company overview and technology

• Focused on commercializing proprietary nanosecond pulsed field ablation (nsPFA) technology for tissue ablation in various clinical settings.

• M-Pulse technology delivers ultra-precise nanosecond electric fields, enabling minimally invasive procedures and improved patient outcomes.

• Over $400 million invested in development, with multiple FDA clearances and a breakthrough device designation.

• Holds more than 215 issued patents and over 100 pending applications, covering systems, applications, and methods.

• Strong leadership, board, and $95.2 million in cash at Q3 end to support ongoing plans.

Differentiation and clinical benefits

• nsPFA delivers higher amplitude, shorter duration pulses than microsecond PFA, enabling deeper, non-thermal ablations.

• Technology permeabilizes intracellular organelle membranes, disrupting mitochondrial function and initiating regulated cell death without thermal damage.

• Enables procedures with lower sedation and non-paralyzing anesthesia, allowing treatment in less intensive care settings.

• Demonstrated significant nodule size reduction and symptom improvement in thyroid ablation without fibrosis or scarring.

• Early feasibility data shows total ablation times of about 12 minutes, compared to 30+ minutes for current devices.

Market strategy and opportunities

• Targeting three initial markets: thyroid intervention, surgical cardiac ablation, and AFib ablation in electrophysiology.

• Combined market opportunity estimated at $6 billion, with potential to more than double over time.

• Employing a hybrid approach: direct entry in addressable markets (e.g., thyroid), partnerships in markets with large competitors (e.g., EP/AFib).

• Engaged in industry discussions to secure partnerships for commercialization, especially in electrophysiology.

• Initial revenues of $86,000 recognized in Q3 from limited market release of M-Pulse Vibrance system.